The Development of a Nano-based Approach to Alleviate Cisplatin-Induced Ototoxicity

  • Mohammad N. Kayyali
  • Andrew J. Ramsey
  • Elizabeth M. Higbee-Dempsey
  • Lesan Yan
  • Bert W. O’MalleyJr
  • Andrew Tsourkas
  • Daqing Li
Research Article


Cisplatin-induced hearing loss is experienced by a high percentage of patients with squamous cell carcinoma undergoing cisplatin chemotherapy. A novel nano-construct capable of sequestering extracellular cisplatin was developed to combat this problem. The nano-construct consisted of superparamagnetic iron oxide nanoparticles (SPIONs) entrapped within polymeric micelles, which were formed from a glutathione diethyl ester-conjugated amphiphilic diblock copolymer. The glutathione-micelles were analyzed at the cellular level and in an organotypic study for safety evaluation. All utilized methods indicated that the micelles do not cause cellular toxicity or organ damage. The micelles’ ability to reduce cisplatin-induced cytotoxicity was then probed in an in vitro model. Cisplatin was pre-treated with the novel nano-construct before being added to growing cells. When compared to cells that were exposed to untreated cisplatin, cells in the pre-treated cisplatin group showed a significant increase in cell viability. This clearly demonstrates that the construct is able to protect the cells from cisplatin cytotoxicity and makes it highly likely that the novel nano-construct will be able to play a role in the protection of the inner ear from cisplatin-induced ototoxicity.


cisplatin thiol nanomicelles cisplatin-induced ototoxicity inner ear 



This work was funded through a National Institute of Health (NIH) grant: 1R01DC014464-01. The authors would like to thank Zheng Cui and Lucia Morstadt for their technical assistance. The authors would also like to thank Dr. Kalinec at UCLA for the donation of the HEI-OC1 cell line.

Compliance with Ethical Standards

Animal care and use was in accordance with the guidelines of the Institutional Animal Care and Use Committee (IACUC) of The University of Pennsylvania and of the National Institute of Health.

Conflict of Interest

The authors declare that they have no conflicts of interest.


  1. Callejo A, Sedó-Cabezón L, Juan ID, Llorens J (2015) Cisplatin-induced ototoxicity: effects, mechanisms and protection strategies. Toxics 3:268-293Google Scholar
  2. Ciarimboli G (2014) Membrane transporters as mediators of cisplatin side-effects. Anticancer Res 34(1):547–550PubMedGoogle Scholar
  3. Devarajan P, Savoca M, Castaneda MP, Park MS, Esteban-Cruciani N, Kalinec G, Kalinec F (2002) Cisplatin-induced apoptosis in auditory cells: role of death receptor and mitochondrial pathways. Hear Res 174(1-2):45–54. CrossRefPubMedGoogle Scholar
  4. Einhorn LH (2002) Curing metastatic testicular cancer. Proc Natl Acad Sci U S A 99(7):4592–4595. CrossRefPubMedPubMedCentralGoogle Scholar
  5. Ellman GL (1959) Tissue sulfhydryl groups. Arch Biochem Biophys 82(1):70–77. CrossRefPubMedGoogle Scholar
  6. Ferraro G, Massai L, Messori L, Merlino A (2015) Cisplatin binding to human serum albumin: a structural study. Chem Commun (Camb) 51(46):9436–9439. CrossRefGoogle Scholar
  7. Freyer DR, Chen L, Krailo MD, Knight K, Villaluna D, Bliss B, Pollock BH, Ramdas J, Lange B, van Hoff D, VanSoelen ML, Wiernikowski J, Neuwelt EA, Sung L (2017) Effects of sodium thiosulfate versus observation on development of cisplatin-induced hearing loss in children with cancer (ACCL0431): a multicentre, randomised, controlled, open-label, phase 3 trial. Lancet Oncol 18(1):63–74. CrossRefPubMedGoogle Scholar
  8. Gebicki JM (2016) Oxidative stress, free radicals and protein peroxides. Arch Biochem Biophys 595:33–39. CrossRefPubMedGoogle Scholar
  9. Gonzalez VM, Fuertes MA, Alonso C, Perez JM (2001) Is cisplatin-induced cell death always produced by apoptosis? Mol Pharmacol 59(4):657–663CrossRefPubMedGoogle Scholar
  10. Ishikawa T, Ali-Osman F (1993) Glutathione-associated cis-diamminedichloroplatinum(II) metabolism and ATP-dependent efflux from leukemia cells. Molecular characterization of glutathione-platinum complex and its biological significance. J Biol Chem 268(27):20116–20125PubMedGoogle Scholar
  11. Ishikawa T, Bao JJ, Yamane Y, Akimaru K, Frindrich K, Wright CD, Kuo MT (1996) Coordinated induction of MRP/GS-X pump and gamma-glutamylcysteine synthetase by heavy metals in human leukemia cells. J Biol Chem 271(25):14981–14988. CrossRefPubMedGoogle Scholar
  12. Jamali B, Nakhjavani M, Hosseinzadeh L, Amidi S, Nikounezhad N, Shirazi FH (2015) Intracellular GSH alterations and its relationship to level of resistance following exposure to cisplatin in cancer cells. Iran J Pharm Res 14(2):513–519PubMedPubMedCentralGoogle Scholar
  13. Jamieson ER, Lippard SJ (1999) Structure, recognition, and processing of cisplatin-DNA adducts. Chem Rev 99(9):2467–2498. CrossRefPubMedGoogle Scholar
  14. Kalinec G, Thein P, Park C, Kalinec F (2016) HEI-OC1 cells as a model for investigating drug cytotoxicity. Hear Res 335:105–117. CrossRefPubMedGoogle Scholar
  15. Karasawa T, Steyger PS (2015) An integrated view of cisplatin-induced nephrotoxicity and ototoxicity. Toxicol Lett 237(3):219–227. CrossRefPubMedPubMedCentralGoogle Scholar
  16. Katzenstein HM, Chang KW, Krailo M, Chen Z, Finegold MJ, Rowland J, Reynolds M, Pappo A, London WB, Malogolowkin M, for the Children's Oncology Group (2009) Amifostine does not prevent platinum-induced hearing loss associated with the treatment of children with hepatoblastoma: a report of the Intergroup Hepatoblastoma Study P9645 as a part of the Children’s Oncology Group. Cancer 115(24):5828–5835. CrossRefPubMedPubMedCentralGoogle Scholar
  17. Laurell G, Viberg A, Teixeira M, Sterkers O, Ferrary E (2000) Blood-perilymph barrier and ototoxicity: an in vivo study in the rat. Acta Otolaryngol 120(7):796–803CrossRefPubMedGoogle Scholar
  18. Lee JW, Pussegoda K, Rassekh SR, Monzon JG, Liu G, Hwang S, Bhavsar AP, Pritchard S, Ross CJ, Amstutz U, Carleton BC, CPNDS Clinical Recommendations Group (2016) Clinical practice recommendations for the management and prevention of cisplatin-induced hearing loss using pharmacogenetic markers. Ther Drug Monit 38(4):423–431. CrossRefPubMedGoogle Scholar
  19. Mahajan S, Koul V, Choudhary V, Shishodia G, Bharti AC (2013) Preparation and in vitro evaluation of folate-receptor-targeted SPION-polymer micelle hybrids for MRI contrast enhancement in cancer imaging. Nanotechnology 24(1):015603. CrossRefPubMedGoogle Scholar
  20. McQuade C, al Zaki A, Desai Y, Vido M, Sakhuja T, Cheng Z, Hickey RJ, Joh D, Park SJ, Kao G, Dorsey JF, Tsourkas A (2015) A multifunctional nanoplatform for imaging, radiotherapy, and the prediction of therapeutic response. Small 11(7):834–843. CrossRefPubMedGoogle Scholar
  21. Park J, An K, Hwang Y, Park JG, Noh HJ, Kim JY, Park JH, Hwang NM, Hyeon T (2004) Ultra-large-scale syntheses of monodisperse nanocrystals. Nat Mater 3(12):891–895. CrossRefPubMedGoogle Scholar
  22. Rabik CA, Dolan ME (2007) Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 33(1):9–23. CrossRefPubMedGoogle Scholar
  23. Rabik CA, Njoku MC, Dolan ME (2006) Inactivation of O6-alkylguanine DNA alkyltransferase as a means to enhance chemotherapy. Cancer Treat Rev 32(4):261–276. CrossRefPubMedGoogle Scholar
  24. Rudolph E, Hann S, Stingeder G, Reiter C (2005) Ultra-trace analysis of platinum in human tissue samples. Anal Bioanal Chem 382(7):1500–1506. CrossRefPubMedGoogle Scholar
  25. Rybak LP, Mukherjea D, Jajoo S, Ramkumar V (2009) Cisplatin ototoxicity and protection: clinical and experimental studies. Tohoku J Exp Med 219(3):177–186. CrossRefPubMedPubMedCentralGoogle Scholar
  26. Thompson DC, Wyrick SD, Holbrook DJ, Chaney SG (1995) HPLC and 31P NMR characterization of the reaction between antitumor platinum agents and the phosphorothioate chemoprotective agent S-2-(3-aminopropylamino)ethylphosphorothioic acid (WR-2721). Biochem Pharmacol 50(9):1413–1419. CrossRefPubMedGoogle Scholar
  27. van den Berg JH, Beijnen JH, Balm AJ, Schellens JH (2006) Future opportunities in preventing cisplatin induced ototoxicity. Cancer Treat Rev 32(5):390–397. CrossRefPubMedGoogle Scholar
  28. Wensing KU, Ciarimboli G (2013) Saving ears and kidneys from cisplatin. Anticancer Res 33(10):4183–4188PubMedGoogle Scholar
  29. Yoo J, Hamilton SJ, Angel D, Fung K, Franklin J, Parnes LS, Lewis D, Venkatesan V, Winquist E (2014) Cisplatin otoprotection using transtympanic L-N-acetylcysteine: a pilot randomized study in head and neck cancer patients. Laryngoscope 124(3):E87–E94. CrossRefPubMedGoogle Scholar

Copyright information

© Association for Research in Otolaryngology 2018

Authors and Affiliations

  • Mohammad N. Kayyali
    • 1
  • Andrew J. Ramsey
    • 1
  • Elizabeth M. Higbee-Dempsey
    • 2
  • Lesan Yan
    • 2
  • Bert W. O’MalleyJr
    • 1
  • Andrew Tsourkas
    • 2
  • Daqing Li
    • 1
  1. 1.Department of Otolaryngology - Head & Neck SurgeryUniversity of Pennsylvania Health SystemPhiladelphiaUSA
  2. 2.Department of BioengineeringUniversity of PennsylvaniaPhiladelphiaUSA

Personalised recommendations